30,477 reports of this reaction
3.9% of all DUPILUMAB reports
#5 most reported adverse reaction
INJECTION SITE PAIN is the #5 most commonly reported adverse reaction for DUPILUMAB, manufactured by sanofi-aventis U.S. LLC. There are 30,477 FDA adverse event reports linking DUPILUMAB to INJECTION SITE PAIN. This represents approximately 3.9% of all 782,562 adverse event reports for this drug.
Patients taking DUPILUMAB who experience injection site pain should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INJECTION SITE PAIN is moderately reported among DUPILUMAB users, representing a notable but not dominant share of adverse events.
In addition to injection site pain, the following adverse reactions have been reported for DUPILUMAB:
The following drugs have also been linked to injection site pain in FDA adverse event reports:
INJECTION SITE PAIN has been reported as an adverse event in 30,477 FDA reports for DUPILUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
INJECTION SITE PAIN accounts for approximately 3.9% of all adverse event reports for DUPILUMAB, making it a notable side effect.
If you experience injection site pain while taking DUPILUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.